|Number||Exon/Intron||Nucleotide change||Protein change||Location||Mutation type||Consequences||Phenotype||Inheritance||Reference|
|450||9||c.1276T>A||p.Tyr426Asn||DI-DII||Missense||P/Oâ†’P/O (143); pLOF||SMEI||De novo||Nabbout R.2003|
|Number||Nucleotide change||Protein change||Location||Phenotype||Functional defect type||Details of the major biophysical abnormalities.||Reference|
|9||c.1276T>A||p.Tyr426Asn(Y426N)||DI-DII (D-linkers)||SMEI||pLOF||Reduced current density, reduced channel availability by negative shift of inactivation and slower recovery from inactivation.||Ohmori I.2006|
|[c.1276T>A] Clinical description|
No detail description in article. Files of current patients with SMEI at participating centers were reviewed by a panel of experts who selected those who fulfilled the following criteria: no history of acquired brain injury; normal cognitive and motor development before seizure onset; onset of febrile or afebrile seizures, generalized or unilateral, before age 1 year; myoclonic jerks; intractable epilepsy; psychomotor delay within 2 years of seizure onset; normal MRI results in the first year of the seizure disorder; and a minimum follow-up of three years(Nabbout R, et al. Neurology. 2003 Jun 24; 60(12): 1961-7. ).
Copyright Â©2014 Institute of Neuroscience and The Second Affiliated Hospital of Guangzhou Medical University
Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China
Collaborative Innovation Center for Neurogenetics and Channelopathies, Guangzhou 510260, China.